Authors: Roisin Conneely
The onslaught of terminations for Alzheimer’s research programs continues with announcements from Merck & Co (NJ, USA) and Boehringer Ingelheim (Rhein, Germany), on the other end of the spectrum approvals have been granted for multiple sclerosis (MS) and neurofibromatosis treatments.
Our highlights from the latest neuroscience and neurology industry headlines:
Phase III verubecestat trial terminated by Merck & Co.
FDA grants delayed approval for MS drug
Boehringer Ingelheim scraps Phase II Alzheimer’s program
Biogen shares fall after announcing patient additions to aducanumab trial
Orphan Drug Designation granted for selumetinib